Gemina Laboratories Ltd.
GLAB
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.88% | 0.11% | 1.35% | -1.66% | -25.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.63% | -10.21% | -13.77% | -26.72% | -42.44% |
| Operating Income | 22.92% | 10.50% | 14.01% | 26.72% | 42.44% |
| Income Before Tax | 17.19% | 9.73% | 10.72% | 23.92% | 47.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.19% | 9.73% | 10.72% | 23.92% | 47.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.19% | 9.73% | 10.72% | 23.92% | 47.27% |
| EBIT | 22.92% | 10.50% | 14.01% | 26.72% | 42.44% |
| EBITDA | 21.21% | 12.16% | 15.49% | 28.04% | 43.70% |
| EPS Basic | 19.17% | 11.59% | 11.70% | 25.47% | 50.44% |
| Normalized Basic EPS | 17.54% | 10.39% | 11.72% | 25.45% | 50.70% |
| EPS Diluted | 19.17% | 11.59% | 11.70% | 25.47% | 50.44% |
| Normalized Diluted EPS | 17.54% | 10.39% | 11.72% | 25.45% | 50.70% |
| Average Basic Shares Outstanding | 2.67% | 2.38% | 1.42% | 1.60% | 5.54% |
| Average Diluted Shares Outstanding | 2.67% | 2.38% | 1.42% | 1.60% | 5.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |